Commission changes COVID-19 vaccines export authorisation for surveillance system
Official publication has been made of Commission Implementing Regulation 2021/2071, by which the European Commission has subjected certain COVID-19 vaccines and active substances used for the manufacture of such vaccines to export surveillance.
These vaccines and some of their active substances are already subject to a prior export authorisation. The export authorisation mechanism, which is set to expire on 31 December, applies to exports from companies with which the EU has concluded Advance Purchase Agreements (AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV, BioNtech-Pfizer, CureVac, and Moderna).
However, the Commission notes that the production and deliveries of COVID-19 vaccine doses in the EU have been accelerated